September 9-11,
2024
STATEN
ISLAND, N.Y., Aug. 26,
2024 /PRNewswire/ -- Acurx Pharmaceuticals, Inc.
(Nasdaq: ACXP), today announced it will be featured as a presenting
company at the H.C. Wainwright 26th Annual Global
Investment Conference. The conference is being held on
September 9-11, 2024.
The in-person venue for the event is the Lotte New York Palace
Hotel in New York City located at
455 Madison Avenue. Virtual participation will be staged
simultaneously with over 550 company presentations scheduled as
live feed or available on-demand.
David P. Luci, President &
CEO of the Company, will provide an overview of the Company's
business during the presentation.
If you are an institutional investor, and would like to listen
to the Company's presentation, please click on the following link
(www.hcwevents.com/annualconference) to register for the
conference. Over 550 corporate presentations & panels are
available during September 9-11,
2024.
Event: H.C. Wainwright 26th
Annual Global Investment Conference
Date: September
9-11, 2024
Location: Virtual to start on-demand on
September 9 at 7:00 A.M. (ET) or in-person location date/time at
the Lotte New York Palace Hotel, New
York, NY.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company
focused on developing a new class of small molecule antibiotics for
difficult-to-treat bacterial infections. The Company's approach is
to develop antibiotic candidates with a Gram-positive selective
spectrum (GPSS®) that blocks the active site of the Gram+ specific
bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA
replication and leading to Gram-positive bacterial cell death. Its
R&D pipeline includes antibiotic product candidates that target
Gram-positive bacteria, including Clostridioides difficile,
methicillin resistant Staphylococcus aureus (MRSA), vancomycin
resistant Enterococcus (VRE) and drug-resistant Streptococcus
pneumoniae (DRSP).
To learn more about Acurx Pharmaceuticals and its product
pipeline, please visit www.acurxpharma.com.
About H.C. Wainwright &
Co.
H.C. Wainwright is a full‐service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides
research and sales and trading services to institutional
investors. According to Sagient Research Systems, H.C.
Wainwright's team is ranked as the #1 Placement Agent in terms of
aggregate CMPO (confidentially marketed public offering), RD
(registered direct offering) and PIPE (private investment in public
equity) executed cumulatively since 1998.
For more information visit H.C. Wainwright & Co. on the web
at www.hcwco.com
Forward-Looking Statements
Any statements in this press release about our future
expectations, plans and prospects, including statements regarding
our strategy, future operations, prospects, plans and objectives,
and other statements containing the words "believes,"
"anticipates," "plans," "expects," and similar expressions,
constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors, including:
whether ibezapolstat will benefit from the QIDP designation;
whether ibezapolstat will advance through the clinical trial
process on a timely basis; whether the results of the clinical
trials of ibezapolstat will warrant the submission of applications
for marketing approval, and if so, whether ibezapolstat will
receive approval from the FDA or equivalent foreign regulatory
agencies where approval is sought; whether, if ibezapolstat obtains
approval, it will be successfully distributed and marketed; and
other risks and uncertainties described in the Company's annual
report filed with the Securities and Exchange Commission on Form
10-K for the year ended December 31,
2023, and in the Company's subsequent filings with the
Securities and Exchange Commission. Such forward-looking statements
speak only as of the date of this press release, and Acurx
disclaims any intent or obligation to update these forward-looking
statements to reflect events or circumstances after the date of
such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & Chief
Executive Officer
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original
content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-announces-participation-at-the-hc-wainwright-26th-annual-global-investment-conference-302229628.html
SOURCE Acurx Pharmaceuticals, Inc.